Drug Details

General Information of the Drug (ID: DR1299)
Name
Paromomycin
Synonyms
paromomycin; Aminosidin; catenulin; AMINOSIDINE; Neomycin E; Hydroxymycin; Zygomycin A1; Crestomycin; Paucimycin; Estomycin; Monomycin A; 7542-37-2; Paromomycine; Paromomycin I; Paramomycin Sulfate; Humatin; Paromomicina; Paromomycinum; Paucimycinum; Antibiotic 503-3; Antibiotic SF 767B; UNII-61JJC8N5ZK; Gabbromycin; Paromomycin (INN); Paromomycin [INN]; R 400; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; 61JJC8N5ZK; Amminosidin; Gabromycin; Humycin; Aminosidine I; Quintomycin C; CHEBI:7934; Antibiotic 2230D; paramomycin sulphate; R-400; Hydroxymycin sulfate; Paramomycin; Monomycin; Paromomycin (TN); Paromomycin sulfate Rx346208; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol; Aminosidine, sulfate; hATT & Paromomycin; Paromomycin [INN:BAN]; Paromomycine [INN-French]; Paromomycinum [INN-Latin]; Paromomicina [INN-Spanish]; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-tetrahydropyran-3,4-diol; EINECS 231-423-0; BRN 0072285; Human .alpha.-1-antitrypsin & Paromomyin; SCHEMBL4072; 4-18-00-07534 (Beilstein Handbook Reference); CHEMBL370143; DTXSID8023424; ZINC60183170; AKOS030489917; DB01421; MCULE-1528618434; NCGC00166210-02; D-Streptamine, O-2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine; C00832; D07467; 10845-EP2301536A1; 10845-EP2301538A1; 10845-EP2311455A1; 10845-EP2316452A1; AB00639998_04; Q415625; PAROMOMYCIN I; AMMINOSIDIN; CATENULIN; CRESTOMYCIN; MONOMYCIN A; NEOMYCIN E; (2R,3S,4R,5R,6S)-5-amino-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)oxane-3,4-diol; Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-O-beta-D-ribofuranosyl-(1-5)-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Amoebiasis [ICD-11: 1A36] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C23H45N5O14
PubChem CID
165580
Canonical SMILES
C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N
InChI
1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
InChIKey
UOZODPSAJZTQNH-LSWIJEOBSA-N
CAS Number
CAS 7542-37-2
ChEBI ID
CHEBI:7934
TTD Drug ID
D04NDM
DrugBank ID
DB01421
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Miltefosine      Coconut leaflet phytoplasma     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression p105  Molecule Info 
Pathway MAP
Up-regulation Expression TNF  Molecule Info 
Pathway MAP
                    In-vitro Model HEK293 CVCL_0045 Healthy Homo sapiens
                    Experimental
                    Result(s)		 The in vitro activity of paromomycin and miltefosine against host cells is TLR4 dependent.
Target and Pathway
Target(s) Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
Reference 2 Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro. J Antimicrob Chemother. 2012 Oct;67(10):2373-8.
Reference 3 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link